Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1CNS 1

Conditions

Ovarian Neoplasms 6Carcinoma, Ovarian Epithelial 4Urinary Bladder Neoplasms 2Neoplasms 2Esophageal Neoplasms 2Endometrial Neoplasms 2Breast Neoplasms 2Uterine Cervical Neoplasms 1Stomach Neoplasms 1Recurrence 1Prostatic Neoplasms 1Lung Neoplasms 1Dysgerminoma 1Central Nervous System Neoplasms 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Carboplatin 19Paclitaxel 17Cisplatin 9Cyclophosphamide 8Gemcitabine 7Bevacizumab 6Topotecan 5pembrolizumab 4olaparib 4liposomal doxorubicin 4durvalumab 4Letrozole 4Interleukin-2 4Drug Therapy 4Doxorubicin 4Albumin-Bound Paclitaxel 4rucaparib 3fludarabine 3chiauranib 3cemiplimab 3camrelizumab 3Therapeutics 3Itraconazole 3Injections 3Hyperthermic Intraperitoneal Chemotherapy 3Everolimus 3pazopanib 2iniparib 2eprenetapopt 2avelumab 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recurrence × Lapatinib × Gynecologic × Clear all
NCT00430781 2015-05-08

Pazopanib Plus Lapatinib Compared to Lapatinib Alone and Pazopanib Alone In Subjects With Metastatic Cervical Cancer

GlaxoSmithKline

Phase 2 Completed
228 enrolled 21 charts
Gynecologic

Uterine Cervical Neoplasms, Neoplasms, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡